Showing 3211-3220 of 6035 results for "".
- Telemedicine Eye Screenings Help Detect Glaucomahttps://modernod.com/news/telemedicine-eye-screenings-help-detect-glaucoma/2476356/A low-cost program using technicians to conduct telemedicine eye screenings can help detect glaucoma in underserved populations, according to new research, as reported by Reuters. The study targeted high-risk individuals in poorer a
- Myco Industries Debuts AB Max Advanced for Treatment of Anterior Blepharitishttps://modernod.com/news/myco-industries-debuts-ab-max-advanced-for-treatment-of-anterior-blepharitis/2476354/Myco Industries released AB MAX, a new treatment for anterior blepharitis. The AB MAX is an adapter that allows eye care professionals to increase the functionality of their Algerbrush by converting it into a multi-purpose device for treatment of the same conditions as a standard Algerbrush, as w
- FDA Grants Breakthrough Device Designation to Concussion Assessment Devicehttps://modernod.com/news/fda-grants-breakthrough-device-designation-to-concussion-assessment-device/2476351/SyncThink announced that the FDA has granted Breakthrough Device Designation to EYE-SYNC, an objective eye-tracking platform. The EYE-SYNC platform is used to assist clinicians in evaluating visual impairments, monitor recovery, and support the rehabilitation of ocular-motor and ocular-vestibular
- New Data From Alcon Shows that Compliant Contact Lens Wear Can Improve Practice Outcomeshttps://modernod.com/news/new-data-from-alcon-shows-that-compliant-contact-lens-wear-can-improve-practice-outcomes/2479590/Alcon unveiled new data from its Power of One 2.0 Program showing how patient compliance with daily and monthly contact lens replacement schedules can significantly improve patient and practice outcomes. The Power of One Program is a contact lens strategy centered on 1-day and 1-month contact len
- WSJ: Roche Nears Deal to Buy Spark Therapeutics for Close to $5 Billionhttps://modernod.com/news/wsj-roche-nears-deal-to-buy-spark-therapeutics-for-close-to-5-billion/2476269/Swiss pharmaceutical company Roche is nearing a deal to buy Philadelphia-based biotechnology company Spark Therapeutics, according to a report in the Wall Street Journal
- Morphic Therapeutic Enters Into Integrin Research and Development Collaboration with J&J’s Janssenhttps://modernod.com/news/morphic-therapeutic-enters-into-integrin-research-and-development-collaboration-with-jjs-janssen/2476272/Morphic Therapeutic announced that it has entered into a research and development collaboration with Johnson & Johnson’s subsidiary Janssen Biotech, to discover and develop novel integrin therapeutics for patients with conditions not adequately addressed by current therapies. Johnson &a
- Allergan Responds to Public Shareholder Letterhttps://modernod.com/news/allergan-responds-to-public-shareholder-letter/2476274/Allergan issued the following statement from its Board of Directors in response to a public shareholder letter from Appaloosa hedge fund manager David Tepper earlier this week that stated the drugmaker should consider a merger or selling itself if it is “unable or unwilling to hold manageme
- Alcon Debuts iLux MGD Treatment System at SECOhttps://modernod.com/news/alcon-debuts-ilux-mgd-treatment-system-for-personalized-therapy-for-dry-eye-disease-at-seco/2476284/Alcon debuted the iLux MGD Treatment System at the SECO International 2019 annual meeting in New Orleans. The device, which received approval from the FDA in December 2017, helps eye care professionals provide comprehensive, in-office
- VSY Biotechnology and Carl Zeiss Meditec Settle Legal Disputeshttps://modernod.com/news/vsy-biotechnology-and-carl-zeiss-meditec-settle-legal-disputes/2476289/VSY Biotechnology BV and Carl Zeiss Meditec AG jointly announced that both companies resolved their legal and patent disputes with respect to the Tri-ED 611 IOL. The companies did not disclose the terms of the settlement.
- Leiters and Mobius Therapeutics Enter into National Sales and Marketing Agreement for Mitosolhttps://modernod.com/news/leiters-and-mobius-therapeutics-enter-into-national-sales-and-marketing-agreement-for-mitosol/2476290/Leiters and Mobius Therapeutics announced that they have entered into a national sales and marketing agreement for Mitosol, the only FDA approved formulation of mitomycin-c bearing an ophthalmic indication. Leiters, an FDA-registered 503B outsourcing provider